SCHEMBL23099178

SCHEMBL23099178

Cc1cnn2ccc(OC(C)C)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
BRD4 O60885 1/20 0.41
BRPF1 P55201 1/20 0.41
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
EPHB3 P54753 1/20 0.36
FGFR1 P11362 1/20 0.35
LRRK2 Q5S007 7/20 0.35
WDR5 P61964 1/20 0.34
PIM3 Q86V86 2/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23087718 0.83 PRMT5 (0.46) PRMT5WDR77BRD4BRPF1ALDH1A1
SCHEMBL31383509 0.83 PRMT5 (0.43) PRMT5WDR77BRD4BRPF1ALDH1A1
SCHEMBL23938061 0.81 EPHB3 (0.46) ALDH1A1KDM4EEPHB3MAPTMEN1
SCHEMBL23099061 0.77 PRMT5 (0.45) PRMT5WDR77ALDH1A1KDM4EHPGD
SCHEMBL23099050 0.76 MAP2K1 (0.45) PRMT5WDR77ALDH1A1KDM4EHPGD
SCHEMBL17132526 0.75 LMNA (0.37) HTT
SCHEMBL31383674 0.74 PRMT5 (0.38) PRMT5WDR77BRD4BRPF1EPHB3
SCHEMBL17133482 0.73 EPHB3 (0.43) ALDH1A1KDM4EEPHB3MAPTHTT
SCHEMBL24149172 0.70 PIK3CA (0.44) PIK3CA
SCHEMBL24370193 0.70 EPHB3 (0.43) EPHB3MAPTMEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479551-B2 MTA-cooperative PRMT5 inhibitors Mirati Therapeutics, Inc. (US) 2022-10-25 US disclosed
US-20210079003-A1 MTA-Cooperative PRMT5 Inhibitors Mirati Therapeutics, Inc. 2021-03-18 US disclosed
US-20210078994-A1 MTA-Cooperative PRMT5 Inhibitors Mirati Therapeutics, Inc. 2021-03-18 US disclosed
WO-2021050915-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2021-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11479551-B2 MTA-cooperative PRMT5 inhibitors PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 133/4885BRD4 166/4885
US-20210079003-A1 MTA-Cooperative PRMT5 Inhibitors PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 226/4885BRD4 84/4885
US-20210078994-A1 MTA-Cooperative PRMT5 Inhibitors PRMT5, PRMT1, PRMT3 PRMT5 1/4885WDR77 226/4885BRD4 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.